Union for International Cancer Control (UICC)
- 1. Largest and oldest global cancer federation
- Founded in 1933, UICC is headquartered in Geneva, Switzerland.
- UICC has a network of over 1,100 members, such as major cancer societies, foundations, ministries of health, and research
institutions on cancer, across 170 countries.
- UICC is the only international cancer organization that represents all cancer types and entire cancer spectrum.
- 2. Close working relation with the agencies of the United Nations
- UICC earned a worldwide reputation for its efforts to encourage governments to ensure that cancer control remains a priority alongside the World Health Organization (WHO) and the World Economic Forum (WEF).
- UICC has an official cooperative relation with WHO and consultative status at the Economic and Social Council (ECOSOC).
- UICC collaborates closely with other key UN agencies including the International Agency for Research on Cancer (IARC), United Nations Office for Drugs and Crime (UNODC), and International Atomic Energy Agency (IAEA).
- 3. Consisted of leaders with global influence
- HRH Princess Dina Mired of Jordan is UICC's President, and its Board of Directors is made up of highly influential figures from countries,
such as Oman, Sweden, Brazil, Malaysia, South Africa, Canada,
and so on, with each one of them representing their regions in the world.
- 4. Annually hosting and participating in cancer-related international platforms
- UICC holds annual international cancer platforms, like the World Cancer Leaders' Summit and the World Cancer Congress.
-Along with partners and members, President of Mexico,
President of Uruguay, Her Majesty Queen of Spain, Her Majesty Queen of Malaysia, HRH Princess of Oman, Ministers of Health, UN agencies
representatives among many others have recently joined UICC-led convening events to raise awareness on cancer control.
- UICC takes part in the UN General Assembly and the WHO-led World Health Assembly every year.
- 5. Introducing World Cancer Day and organizing global cancer campaigns
-Since 2008, World Cancer Day is celebrated on 4 February, and World Cancer Day was created
under the leadership of UICC to support and organize global campaigns for cancer awareness and prevention.
- Recently, 55 landmarks illuminated in 37 cities, 947 activities in 127 countries,
over 15,000 press articles in 154 countries, and 62 governments' direct engagement have been recorded.
Patron Partnership Agreement and Program Co-Development and Launch Agreement
- 1. Signing of Patron partnership agreement, the highest partnership level within UICC
- UICC builds an extensive network of partners including major cancer societies, international organizations, foundations,
and corporations for the elimination of cancer in all countries.
- UICC has more than 1,100 members and 53 partners, including major cancer societies, foundations, ministries of health, hospitals, and research centers on cancer
, across 170 countries, and only 9 of them are Patron partners, the highest partnership level within UICC.
- Patron partners work closely with UICC to lead the change in the practical implementation of cancer-related policies for timely
and accurate cancer diagnosis and treatment and eventually create a long-lasting and positive impact on societal progress.
- Patron partners are entitled to special benefits, such as the development of exclusive cancer-related programs and the opportunity to give a speech on international platforms, like the World Cancer Leaders' Summit.
- UICC's Patron partners include globally famous pharmaceutical companies,
like Pfizer and Roche, and its other partners involve Novartis, AMGEN, Merck, Johnson & Johnson, Bayer, etc..
- 2. The world's first small and medium-sized enterprise to join UICC as its Patron partner
- Since Patron partners are given opportunities to exert more influence on the world, the hasty selection of any Patron partner may undermine
UICC's worldwide reputation. For this reason, the selection process is neither simple nor easy.
- CUBEBIO joins UICC as a Patron partner after this particular selection process and is afforded an opportunity to be in the same league as
international pharmaceutical corporations, like Pfizer and Roche, in the field of cancer diagnosis.
- 3. The world's first partner to have signed Patron partnership and program agreements at the same time
- UICC keeps its close working relations with partners and develops diverse programs in order to generate substantive impacts in relation to cancer diagnosis and treatment around the world.
- Patron partners develop cancer-related programs with UICC and extend these programs' reach and impact by making use of UICC's vast network of partners and members.
- Major partners of UICC's programs are Pfizer and Roche among others, and they are internationally large companies
and have been UICC's Patron partners for many years. It is an unprecedented case that
a new Patron partner, like CUBEBIO, signs the partnership agreement and the program agreement at the same time.
- 4. Co-Development and launching of an exclusive global program, called CUBEBIO-UICC Cancer Early Detection and Self-Diagnosis
- Self-diagnosis enables anyone to check for cancer easily, accurately, and frequently in various settings, such as home, clinics, and hospitals. Early detection of cancer
increases the chances of making a full recovery and significantly reduces financial burdens. Therefore, the concept and trend of self-diagnosis
that CUBEBIO presents aligns with UICC's mission and key strategies and has led to the co-development and launching of the program.
- 5. Opportunities to gain global visibility and influence through activities on international platforms
- CUBEBIO is invited to attend the 2019 World Cancer Leaders' Summit in Kazakhstan as UICC's Patron partner.
- CUBEBIO will raise awareness on the necessity and importance of early detection through self-diagnosis, which can ultimately protect people around the world from cancer.
- CUBEBIO will organize sessions for people's health improvement through self-diagnostic technology by inviting major cancer societies, royal foundations, ministries of health, CEO, UN agencies among others.
CUBEBIO will also encourage the implementation of policies by sharing early detection-related data and technology.
- CUBEBIO will participate in UN General Assembly and WHO-led World Health Assembly and host conferences with UICC to raise awareness on the significant contribution
self-diagnostic technology can make to reducing global cancer incidence and mortality rates. Therefore, the status of
CUBEBIO and South Korea where the company is located will increase within and beyond international medical and scientific cancer communities.
《Standart-Biotest》 LLC (Russia)《Standart-Biotest》 LLC is a Russian corporation conducting the wholesale business of pharmaceutical products, medical machinery, devices, and equipment as well as the production of medicinal supplies.
Since 2017, the Ministry of Health of the Russian Federation has enacted a policy where Russian citizens mandatorily receive regular cancer checkups once every three years, and 《Standart-Biotest》 LLC was established for the implementation of the policy.
Accordingly, 《Standart-Biotest》 LLC is supported by the National Medical Research Radiological Centre, the Federal State Budgetary Institution of the Ministry of Health of the Russian Federation and the Ministry of Health of the Russian Federation and is leading the advancement of the field of cancer diagnosis in the Russian market for the implementation of the national health strategy in relation to cancer diagnosis and treatment.
National Medical Research Radiological Centre (Russia)The National Medical Research Radiological Centre is the Federal State Budgetary Institution of the Ministry of Health of the Russian Federation.
The National Medical Research Radiological Centre consists of Hertsen Moscow Oncology Research Institute, the oldest cancer research center in Europe founded in 1898, Tsyb Medical Radiological Research Centre, and Lopatkin Scientific Research Institute of Urology and Interventional Radiology.
The National Medical Research Radiological Centre has 905 beds and over 3,300 medical professionals.
The National Medical Research Radiological Centre partners with international institutions, including the International Agency for Research on Cancer (IARC), the International Atomic Energy Agency (IAEC), and the European Organization for Research and Treatment of Cancer (EORTC).
The National Medical Research Radiological Centre is a member of the Union for International Cancer Control (UICC).